Jump to content

Drilldown/Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Classic Psychedelic

or Opioid

or [[:Category:Psychostimulants|Psychostimulant]]

Use the filters below to narrow your results.

Other values:

5-HT2A agonist (26) · Potent mu-opioid receptor agonist (6) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Mu-opioid receptor agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Contains LSA (2) · Contains mescaline (2)

Other values:

None (100) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"' (1)

None (99) · ADHD: 30 mg PO once daily in the morning; titrate by 10-20 mg weekly to clinical effect. Binge-eating disorder: 30 mg/day, titrate to 50-70 mg/day (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Narcolepsy/OSA: 200 mg PO once daily in the morning. Shift work disorder: 200 mg PO approximately 1 hour before the start of the work shift. Lower starting dose (100 mg) can be considered in elderly patients or those with hepatic impairment. (1)

None (99) · Capsules 10, 20, 30, 40, 50, 60, 70 mg; chewable tablets 10, 20, 30, 40, 50, 60 mg (1) · Oral tablets 100 mg and 200 mg (Provigil and generics). No IV or extended-release formulations available; compare armodafinil (Nuvigil) 50/150/250 mg tablets as the R-enantiomer alternative. (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (99) · 360 mg/day (1) · 400 mg/day (though clinical trials and FDA label note that doses above 200 mg/day have not demonstrated additional benefit in controlled studies for the approved indications; 200 mg is the standard therapeutic dose).'"`UNIQ--ref-0000004B-QINU`"' (1) · 70 mg/day (1)

None (98) · Oral (2) · Oral only. (1) · PO (only formulation marketed in the US). (1)

None (98) · 1-2 hours (slower than immediate-release amphetamine because activation requires enzymatic cleavage in red blood cells) (1) · 30–60 min (PO) (1) · 30–60 minutes (1) · Peak plasma concentrations 2-4 hours after oral dose. Wakefulness-promoting effect onset correlates with peak plasma; subjective alertness typically reported within 1-2 hours of dosing. (1)

None (98) · 10-12 hours (smoother profile than immediate-release amphetamine salts) (1) · 4–6 hours (1) · 8–12 hours (1) · Effective wakefulness promotion through approximately 12-15 hours reflecting the half-life of the predominant R-enantiomer. For shift-work use, 200 mg taken 1 hour before shift provides coverage through most 8-12 hour shifts. (1)

None (99) · 2.5–3 hours (1) · 3–5 hours (1) · Parent lisdexamfetamine <1 hour; dextroamphetamine 10-12 hours after release'"`UNIQ--ref-00000017-QINU`"' (1)

None (98) · 70–90% (oral) (1) · Approximately 80% (well-absorbed orally; not significantly affected by food, though food may delay Tmax by ~1 hour).'"`UNIQ--ref-0000004D-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~96% after red blood cell hydrolytic cleavage releases dextroamphetamine'"`UNIQ--ref-00000018-QINU`"' (1)

None (99) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited human data; the amphetamine class is associated with intrauterine growth restriction and neonatal withdrawal symptoms.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Not established (1)

None (99) · Schedule I (United States) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Schedule II|Schedule II controlled substance]] in US'"`UNIQ--ref-00000019-QINU`"' (1)

Showing below up to 102 results in range #1 to #102.

1

2

4

5

7

7-Hydroxymitragynine

A

B

C

D

E

F

Fentanyl

H

K

Kratom

L

M

N

Nalbuphine

O

P

R

Remifentanil

S

T

U

U-47700

Y

Yopo

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"